Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’s
Chris Boshoff played role in drugmaker’s acquisition of Seagen, which has been criticised by investor
Danish company expects data to show that CagriSema cuts weight by 25 per cent in just over a year
Acquisition is latest example of western drugmakers turning to China to tap innovation
Potential wider uses should maintain investor enthusiasm and fuel ongoing competition
Pharmaceutical companies turn to jurisdictions with simpler regulatory regimes
Analysis points to potential of drugs such as Ozempic beyond tackling obesity and diabetes
Drug company made claims even though a study of donanemab’s preventive potential is not due to end until 2027
CBO analysis says savings from other health benefits would not offset expense of weight-loss jabs
US biotech researches treatments to reduce muscle loss from blockbuster diet medicines
The company is thriving as weight-loss drugs boom, but investors see warning signs it has reached ‘peak enthusiasm’
Swiss pharma group is a high spender on R&D but has had misses in Alzheimer’s and cancer
Latest setback for Dato-DXd comes after disappointing results in lung cancer treatment earlier this month
Results offer hope of progress in combating bladder tumours and some forms of breast cancer
High rates of vomiting among those who took strong doses in trials have unsettled investors
Danish pharma company also unveils early data for closely watched oral pill to tackle weight loss
Failure to reach statistical significance sets back effort to build oncology portfolio
Medical breakthroughs come with spiralling price tag, leaving policymakers with tough decisions
A three-part FT series looks at how an influx of money is changing prospects for patients but creating new challenges for healthcare systems
Pandemic winners BioNTech and Moderna face hurdles as they seek to bring their groundbreaking technology to oncology
More trials urged as part of effort to slow cognitive declines with existing medicines
Nice’s ruling on lecanemab demonstrates the lack of readiness to roll out new treatments in the UK
US group races to overcome production bottleneck to meet demand for anti-obesity medicine Zepbound
The first in an FT series looking at the new energy behind the fight for cancer cures
Pharma groups are finally turning their research focus to a huge unmet need
